Stifel keeps USD 76.43 target for Globus Medical stock
Published on 10/17/2026 at 20:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSStifel maintains its view
- Stifel analyst Thomas Stephan reiterated a Hold rating and set a USD 76.43 target on October 8, 2026.
- Globus Medical will release third-quarter 2026 results on November 5, 2026.
- Globus Medical stock last stood at USD 76.71 on October 16, 2026 at 4:00 p.m. ET, down 2.70 percent on the NYSE.
- Globus Medical had a USD 10.3 billion market capitalization and a 19.72 price-to-earnings ratio on October 16, 2026.
Stifel Nicolaus analyst Thomas Stephan reiterated a Hold rating for Globus Medical and set a USD 76.43 price target on October 8, 2026, according to The Globe and Mail. The target was 0.37 percent below the last NYSE price of USD 76.71. Globus Medical stock last stood at USD 76.71 on October 16, 2026 at 4:00 p.m. ET, down 2.70 percent on the NYSE.
Results date is November 5
Globus Medical will announce results for the third quarter ended September 30, 2026 after the market close on November 5, 2026. The company also scheduled a conference call for 4:30 p.m. Eastern Time that day, according to GlobeNewswire.
Price sits below the yearly high
The NYSE price ranged from USD 76.49 to USD 79.78 on October 16, 2026, while trading volume reached 1,940,431 shares against an average of 1,436,295. The latest price was 24.35 percent below the 52-week high of USD 101.40 and 28.90 percent above the 52-week low of USD 59.51. These levels place the stock closer to the lower half of its annual range than to its yearly peak.
Valuation and medical-device peers
Globus Medical had a USD 10.3 billion market capitalization and a 19.72 price-to-earnings ratio on October 16, 2026. Its valuation was below Stryker's 30.53 ratio and Medtronic's 23.34 ratio, although the three companies operate at different scales.
Comparison with peers
GMED: minus 2.70 percent, P/E 19.72, market capitalization USD 10.3 billion. Stryker (NYSE, USD): plus 0.49 percent, P/E 30.53, market capitalization USD 113.0 billion. Medtronic (NYSE, USD): minus 0.73 percent, P/E 23.34, market capitalization USD 121.2 billion.
What comes next for the stock
The November results will provide the next scheduled test of Globus Medical's operating performance after the October target update. For investors, the immediate tension is clear in the numbers: the stock's 19.72 price-to-earnings ratio is below both listed peers, while its USD 101.40 yearly high remains 24.35 percent away.
Globus Medical is listed on the NYSE under ticker GMED and develops musculoskeletal technology for spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. Its investor-relations page identifies Audubon, Pennsylvania as the company's base and lists the November 5, 2026 earnings event.
Stock position and next date
The stock's 2.70 percent decline on October 16, 2026 was accompanied by volume above its average, while the price remained above the annual low. The next dated company event is the third-quarter release on November 5, 2026.
Globus Medical stock last stood at USD 76.71 at 4:00 p.m. ET on October 16, 2026 on the NYSE, down 2.70 percent on the day.
Globus Medical stock at a glance
- Company: Globus Medical, Inc.
- ISIN: US3795772082
- Ticker: GMED
- Primary exchange: NYSE
- Price at NYSE (as of October 16, 2026, 4:00 p.m. ET): USD 76.71
- Change on the NYSE: minus 2.70 percent
- Market capitalization: USD 10.3 billion (as of October 16, 2026)
- 52-week range: USD 59.51-101.40 (as of October 16, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Next earnings date: November 5, 2026
Market context: Market report S&P 500.
